Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed, unresectable locally advanced (stage IIIB with pleural effusion) and/or metastatic (stage IV) NSCLC * Progression to first-line therapy for advanced/metastatic NSCLC * Bi-dimensionally measurable disease (not included in radiation field) * ECOG performance status of 0-2 * Life expectancy of more than 6 months * Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases,adequate renal function (serum creatinine \<1.5 times the upper normal limit),and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function * Signed informed consent Exclusion Criteria: * Central nervous system involvement (unless if the patient has being previously irradiated and is clinically stable) * Presence of a centrally located mass or a tumor mass in close relation to large vessels or a mass with cavitation. * Surgery or radiation therapy within the last 14 days from study entry * Active infection * History of life-threatening hemoptysis / hematemesis, history of thrombosis or use of anti-coagulation therapy * History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction, ventricular arrhythmias) or stroke within the previous 6 months or uncontrolled hypertension * Patients on other experimental treatment protocols * History of a second primary malignancy (other than basal-cell skin carcinoma or in situ carcinoma of the cervix) * Psychiatric illness or social situation that would preclude study compliance * Pregnant or lactating women